Summary
GDC-0449 is an oral agent that will be added to "standard" therapy in metastatic colorectal carcinoma (CRC) and evaluating progression free survival as the primary objective.
Analysis
Good trial with an appropriate randomization. This should tell us if the agent has a future in this rather common cancer. A well spent 3 million dollars by Genentech. Chance of benefit?? At least the study is designed to answer the question.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
